Merck launches next-generation cell culture media perfusion processes

Merck launches next-generation cell culture media for perfusion processes

11:09 AM, 16th May 2017
Merck launches next-generation cell culture media for perfusion processes
Exceptional performance and consistency required for high-density perfusion cell culture processes.

DARMSTADT, GERMANY: Merck increases manufacturing flexibility and enabling higher productivity with the launch of the EX-CELL Advanced HD Perfusion Medium. This first off-the-shelf, high-density cell culture media supports perfusion processes at low perfusion rates, increasing production yield and speed to a clinic. 

Biomanufacturers are moving toward perfusion processes, the next generation in manufacturing, as they seek to cut costs while increasing quality and efficiency. Perfusion processes, however, require a new type of medium. Merck’s EX-CELL Advanced HD Perfusion Medium meets “next-gen” manufacturing requirements, allowing customers to achieve a more optimal output than they would use conventional batch or fed-batch processes.

A benefit of perfusion processing is higher protein yields, compared with fed-batch, which has been the primary mammalian cell cultivation mode for biopharma manufacturing over the past few decades. Perfusion technology is compatible with small portable plants and can be used with many drug types over a range of production scales.

Merck’s EX-CELL Advanced HD Perfusion Medium is the most recent addition to the company’s EX-CELL Advanced product line, which offers increased performance, streamlines regulatory compliance and provides the supply chain security needed in today’s evolving biopharmaceutical environment.

“This launch is a major milestone on the road to truly enabling next generation processing. The benefits of perfusion technology include increased cost efficiency, decreased risk and enhanced manufacturing flexibility—ultimately advancing our customers’ production capabilities and increasing access to therapies for people worldwide,” said Udit Batra, member of the Merck executive board and CEO, life science.

© Worldofchemicals News 

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


IFF prices $500 million of senior notes due 2047

NEW YORK, US: International Flavors & Fragrances Inc (IFF) said that it has priced an underwritten public offering of $500 million in aggregate pr ...

Read more
BioAmber makes changes to board, appoints new CFO

MONTREAL, US: BioAmber Inc (BIOA) said that it is has appointed Robert Frost to its board of directors, effective immediately. Frost is a Partner ...

Read more
ExxonMobil announces positive results on Muruk-1 sidetrack well

IRVING, US: ExxonMobil Corporation (XOM) announced positive results on the Muruk-1 sidetrack well in the Papua New Guinea (PNG) North Highlands, ...

Read more
XactCO2: Praxair’s innovative beverage carbonation fill system

DANBURY, US: NuCO2, a subsidiary of Praxair Inc (PX) has launched XactCO2 HP (high-pressure) patent-pending fill system, a permanent, scalable carbon ...

Read more
Merck, Stelis opens first process scale-up lab in Bengaluru, India

DARMSTADT, GERMANY: Merck Group in collaboration with Stelis Biopharma Pvt Ltd has opened its first joint process scale-up lab in Bengaluru, India. Th ...

Read more
Ashland completes final separation of Valvoline

COVINGTON, US: Ashland Global Holdings Inc (ASH) said that it has completed the previously announced distribution of 170,000,000 shares of common stoc ...

Read more